Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds independent research and innovation in cystic fibrosis, pain, IgA nephropathy, and rare diseases that align with its scientific priorities.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (CF, Pain, IgA nephropathy ISS, grants, sponsorships) | Next cycle opens in 2026 (CF Research Innovation Awards, VIA, Circle of Care)
Funding Amounts: No strict cap; typical ISS, grant, and sponsorship awards are based on fair market value and project needs. RIA and VIA: up to $750,000 over 2–3 years.
Summary: Supports independent research, education, and innovation in cystic fibrosis, pain, IgA nephropathy, and other serious diseases aligned with Vertex’s priorities.
Key Information: ISS, grants, and sponsorships are accepted year-round; specific RFPs/cycles apply for some programs.
Description
Vertex Pharmaceuticals funds a broad portfolio of programs to advance scientific research, healthcare professional education, patient advocacy, and innovation in serious diseases, with a core focus on cystic fibrosis, pain, IgA nephropathy, beta thalassemia, sickle cell disease, and select rare disorders. Funding is available for investigator-sponsored studies (ISS), educational grants, organizational sponsorships, and competitive research awards. Support is provided to independent investigators, academic institutions, healthcare professionals, and organizations whose projects align with Vertex’s scientific and clinical interests, aiming to expand knowledge, improve patient care, and foster collaboration.
